| View |
BR-906_PI_01.pdf
|
BR-906
|
Golimumab
|
Simponi
|
50 mg/0.5 mL
|
Solution For Injection (SC)
|
-
|
Baxter Pharmaceutical Solutions LLC
|
United States of America
|
Initial
|
15 March 2022
|
14 May 2026
|
| View |
|
BR-909
|
Enoxaparin Sodium
|
Enoclex
|
60mg/0.6mL
|
Solution For Injection (SC)
|
Antithrombotic Agent
|
Shenzhen Techdow Pharmaceutical Co., Ltd.
|
China
|
Automatic Renewal
|
14 April 2023
|
21 May 2028
|
| View |
|
BR-911
|
LIVE ATTENUATED MEASLES, MUMPS and RUBELLA VACCINE
|
NONE
|
10 Dose
|
Freeze- Dried Powder For Injection ( S.C )
|
VACCINE
|
Serum Institute of India Ltd.
|
India
|
Renewal
|
21 March 2023
|
21 May 2028
|
| View |
|
BR-916
|
Choriogonadotropin Alfa
|
Ovidrel
|
250 mcg/0.5 mL
|
Solution for Injection (SC)
|
-
|
Merck Serono S.p.A.
|
Italy
|
Renewal
|
31 March 2023
|
23 July 2028
|
| View |
|
BR-917
|
Measles, Mumps and Rubella Vaccine (Live,
Attenuated)
|
M-M-R II
|
REMARKS:
Formulation:
After reconstitution, each dose (0.5 mL) contains:
Live, attenuated virus derived from Edmonston B strain of measles………………… 3.0 log TCID50*
Live, attenuated Jeryl Lynn strain of mumps…………..4.1 log TCID50*
Live, attenuated Wistar RA27/3 strain of rubella. …………3.0 log TCID50*
*TCID 50 - Tissue Culture Infectivity Dose 50%
|
Lyophilized Powder for Solution for Injection (IM/SC)
|
-
|
Merck Sharp and Dohme LLC
|
U.S.A
|
Renewal
|
26 April 2023
|
26 January 2028
|
| View |
|
BR-918
|
Clostridium Botulinum Toxin Type A
|
HugelTox
|
100 Units
|
Lyophilized Powder For Injection
|
Muscle Relaxant
|
Hugel, Inc.
|
Korea
|
Renewal
|
22 March 2023
|
07 August 2028
|
| View |
|
BR-919
|
Diphtheria, Tetanus, Pertussis (Acellular Component), Hepatitis B, Poliomyelitis (Inactivated) and Haemophilus influenzae Type B Conjugate Vaccine (Adsorbed)
|
Hexaxim
|
Formulation:
Each dose (0.5 mL) contains: Diphtheria toxoid'
Tetanus toxoid '
Bordetella pertussis antigen
Pertussis toxoid'
Filamentous hemagglutinin' Poliovirus (Inactivated)2.3 Type I (Mahoney) strain
NLT 20 IU NLT 40 IU
Hepatitis B surface antigen Haemophilus influenzae Type B
Polysaccharide Phosphate)
10 mcg
(Polyribosylribitol 12 mcg
Conjugate to Tetanus protein
22-36 mcg
25 mcg
25 mcg
40 D antigen units
Type II (MEF-1) strain"
Type III (Saukett) strain1
8 D antigen units
32 D antigen units
'adsorbed on aluminium hydroxide, hydrated (Al(OH)3)
2produced in yeast cells (Saccharomyces cerevisiae) by recombinant DNA technology
3adsorbed on aluminium phosphate (AIPO4)
*propagated in VERO cells
|
Suspension for Injection (IM)
|
Vaccines
|
Sanofi Pasteur
|
France
|
Renewal
|
04 September 2023
|
29 August 2028
|
| View |
|
BR-920
|
Filgrastim (Recombinant Human Granulocyte Colony Stimulating Factor)
|
White-C
|
300 mcg/mL
|
Solution For Injection
|
Hematopoietic Growth Factor
|
Shandong Kexing Bioproducts Co., Ltd.
|
China
|
Renewal
|
27 December 2018
|
03 September 2028
|
| View |
|
BR-921
|
Human Rabie Immunoglobulin
|
H-Ryg
|
100IU/mL
|
Solution For Injection (IM)
|
Immunoglobulin
|
Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd.
|
China
|
Automatic Renewal
|
07 January 2022
|
03 September 2026
|
| View |
|
BR-922
|
Human Tetanus Immunoglobulin
|
H-Tyg
|
100IU/mL
|
Solution For Injection (IM)
|
Immunoglobulins
|
Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd.
|
China
|
Automatic Renewal
|
07 January 2022
|
03 September 2026
|
| View |
|
BR-923
|
Japanese Encephalitis Vaccine (Live, Attenuated)
|
Imojev
|
Formulation: After reconstitution, one dose (0.5 mL) contains 4.0-5.8 log Plaque Forming Units (PFU) live, attenuated, recombinant Japanese Encephalitis Virus.
|
Powder for Suspension for Injection (SC)
|
-
|
Government Pharmaceutical Organization - Merieux Biological Products Co., Ltd.
|
Thailand
|
Initial (Variation)
|
13 July 2022
|
13 July 2027
|
| View |
|
BR-925
|
Human Papillomavirus Vaccine [Types 16 and 18]
(Recombinant, adjuvanted, adsorbed)
|
Cervarix
|
Formulation:
1 dose (0.5 mL) contains:
Human Papillomavirus type 16 L1 protein*.
Human Papillomavirus type 18 L1 protein*.
.20 mcg ...... 20 mcg
*adjuvanted by AS04 containing 3-O-desacyl-4'-monophosphoryl lipid A (MPL) and Aluminum hydroxide, hydrated [Al(OH)3]
|
Suspension for Injection (IM)
|
Vaccine
|
GlaxoSmithKline Biologicals SA
|
Belgium
|
Renewal (Reconstruction)
|
22 February 2024
|
23 March 2027
|
| View |
|
BR-929
|
Poliomyelitis Vaccine (Type 1, 2 and 3) (Inactivated)
|
Imovax Polio
|
Formulation:
Each dose (0.5 mL) contains:
Poliovirus type 1, Mahoney strain (inactivated)....... 40 D antigen units
Poliovirus type 2, MEF-1 strain (inactivated)........... 8 D antigen units
Poliovirus type 3, Saukett strain (inactivated)............32 D antigen units
|
Suspension for Injection (IM/SC)
|
Vaccines
|
Sanofi Pasteur
|
France
|
Renewal
|
03 January 2024
|
31 October 2028
|
| View |
|
BR-938
|
Epoetin alfa
|
Renogen
|
2000 IU/mL
|
Solution for Injection (IV/SC)
|
Antianemic Preparations
|
Intas Biopharmaceuticals Ltd.
|
India
|
Renewal
|
12 January 2024
|
18 March 2029
|
| View |
|
BR-939
|
Enoxaparin Sodium
|
Enoclex
|
40 mg/0.4 mL
|
Solution For Injection (S.C.)
|
Antithrombotic Agent
|
Shenzhen Techdow Pharmaceutical Co., Ltd.
|
China
|
Renewal
|
24 October 2023
|
14 April 2029
|
| View |
|
BR-940
|
Epoetin alfa (Recombinant Human Erythropoietin)
|
Renogen
|
4,000 IU/mL
|
Solution for Injection (IV/SC)
|
Hematopoietic Growth Factor
|
Intas Biopharmaceuticals Ltd.
|
India
|
Automatic Renewal (E-AR)
|
05 January 2024
|
14 April 2029
|
| View |
|
BR-948
|
Insulin Human (rDNA)
|
Humulin N Kwikpen
|
100 IU/mL
|
Suspension For Injection (S.C.)
|
Antidiabetics
|
Lilly France(Fegersheim)
|
France
|
Renewal
|
19 January 2024
|
27 May 2029
|
| View |
|
BR-950
|
Insulin Human (rDNA)
|
Humulin 70/30 Kwikpen
|
100 IU/mL
|
Suspension For Injection (S.C.)
|
Antidiabetics
|
Lilly France(Fegersheim)
|
France
|
Renewal
|
24 January 2024
|
27 May 2029
|
| View |
|
BR-952
|
Trastuzumab Emtansine
|
Kadcyla
|
160 mg
|
Powder For Conc. For Sol'N For Iv Infusion
|
Monoclonal Antibody
|
F. Hoffmann-La Roche AG
|
Switzerland
|
Renewal
|
10 May 2024
|
30 June 2029
|
| View |
|
BR-953
|
Trastuzumab Emtansine
|
Kadcyla
|
100 mg
|
Powder For Concentrate For Solution For I.V. Infusion
|
Monoclonal Antibody
|
F. Hoffmann-La Roche AG
|
Switzerland
|
Renewal
|
06 May 2024
|
30 June 2029
|